Skip to main content
  • Oral presentation
  • Open access
  • Published:

Immune activation and MRgFUS

Background/introduction

For many years, immune activation following tumor ablation has been evaluated in the treatment of systemic cancer. Ultrasound ablation is thought to promote dendritic cell maturation and T-cell immunity, and is particularly advantageous because it is non-invasive, can be controlled with high spatial precision and uses no harmful ionizing radiation.

Methods

Recently, immune adjuvants have been shown to be effective in treating metastatic cancer, with cancer immunotherapy named as the “breakthrough of the year” in 2013. At this time, combining ablation with immune adjuvants is a promising technique for expanding the utility of ultrasound for the treatment of systemic disease. We will briefly review the status of this combined therapy and opportunities for future studies.

Author information

Authors and Affiliations

Authors

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ferrara, K., Ingham, E., Wong, A. et al. Immune activation and MRgFUS. J Ther Ultrasound 3 (Suppl 1), O41 (2015). https://doi.org/10.1186/2050-5736-3-S1-O41

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/2050-5736-3-S1-O41

Keywords